|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-12-20
|
|
pubmed:abstractText |
OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD) over PLD alone in relapsed ovarian cancer. The optimal management of patients with partially platinum-sensitive relapse [6-12 months platinum-free interval (PFI)] is unclear.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:AlfaroVV,
pubmed-author:ChanSS,
pubmed-author:ColomboNN,
pubmed-author:Filipczyk-CisarzEE,
pubmed-author:GómezJJ,
pubmed-author:HagbergHH,
pubmed-author:KayeS BSB,
pubmed-author:KoneDD,
pubmed-author:LebedinskyCC,
pubmed-author:MonkB JBJ,
pubmed-author:ParekhTT,
pubmed-author:ParkY CYC,
pubmed-author:PovedaAA,
pubmed-author:RoyMM,
pubmed-author:TjulandinSS,
pubmed-author:VergoteII
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
39-48
|
|
pubmed:meshHeading |
pubmed-meshheading:20643862-Adult,
pubmed-meshheading:20643862-Aged,
pubmed-meshheading:20643862-Aged, 80 and over,
pubmed-meshheading:20643862-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20643862-Dioxoles,
pubmed-meshheading:20643862-Disease-Free Survival,
pubmed-meshheading:20643862-Doxorubicin,
pubmed-meshheading:20643862-Drug Administration Schedule,
pubmed-meshheading:20643862-Female,
pubmed-meshheading:20643862-Humans,
pubmed-meshheading:20643862-Middle Aged,
pubmed-meshheading:20643862-Multivariate Analysis,
pubmed-meshheading:20643862-Organoplatinum Compounds,
pubmed-meshheading:20643862-Ovarian Neoplasms,
pubmed-meshheading:20643862-Polyethylene Glycols,
pubmed-meshheading:20643862-Recurrence,
pubmed-meshheading:20643862-Tetrahydroisoquinolines,
pubmed-meshheading:20643862-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
|
|
pubmed:affiliation |
Area of Gynecologic Oncology, Valencian Institute of Oncology, Valencia, Spain. apoveda@fivo.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
